Spotting undervalued shares, Savills & weight-loss drugs: The Companies and Markets Show
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Spotting undervalued shares, Savills & weight-loss drugs: The Companies and Markets Show
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
We begin with Hugh Moorhead and recent results from Savills (SVS), which were in line with expectations. Hugh and Dan unpack what divisions brought in the highest profits, a breakdown of a handful of global performances, and what the business’s valuation appears to be.
Next up James Norrington joins to unpack our latest Big Read on sum-of-the-parts valuations. James explains the thinking behind the piece, how it can help find stocks trading at less than their worth, and how to tell if a company is focusing on the right part of a business.
Lastly, Julian Hofmann covers Novo Nordisk (DK:NOVO.B), which saw shares rise after Eli Lilly’s (US:LLY) oral weight-loss pill underwhelmed regulators. Competition is still fierce in the sector, but a new Novo CEO could give the company the boost it needs.
Read more on these topics
How to spot undervalued shares
Deep Dives
Timestamps
1:16 Savills
13:41 Spotting undervalued shares
26:33 Weight loss drugs
Hosted on Acast. See acast.com/privacy for more information.